FDA clears short­er treat­ment reg­i­men for Ab­b­Vie's hep C treat­ment, Mavyret. Will pa­tients ben­e­fit?

Ab­b­Vie $AB­BV has ob­tained FDA ap­proval to ad­min­is­ter its Mavyret he­pati­tis C pill as a two-month reg­i­men, ver­sus the 12-week course it was orig­i­nal­ly cleared for — a move that may help ex­pand op­tions for the mar­gin of cov­ered pa­tients who need a short­er reg­i­men.

“While over 100,000 pa­tients have been pre­scribed Mavyret for chron­ic HCV in the US, there are still a sig­nif­i­cant num­ber of pa­tients that need op­tions,” Janet Ham­mond, Ab­b­Vie’s vice pres­i­dent of gen­er­al med­i­cine and vi­rol­o­gy ther­a­peu­tic area, said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER